Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline Deferred Investment Award Programme.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share transaction notifications.
Material Changes
On July 16, 2013, the Administrators notified the Company of increases in notional interests in Ordinary Shares for specific individuals following the re-investment of the dividend paid on July 11, 2013. The transaction price was 1750.75 pence per Share.
- Mr S A Hussain: 271.623 shares
- Mr D S Redfern: 60.727 shares
- Ms C Thomas: 37.955 shares
- Ms E Walmsley: 558.474 shares
- Mrs V A Whyte: 148.121 shares
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The report is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the dividend re-investment price of 1750.75 pence per Share.
- Confirm the specific share increases for the named directors and managers.
- Note that this filing does not contain financial performance data for the period.